April 4, 2011 -- Pfizer has agreed to co-promote a hypertension drug from Daiichi Sankyo Pharma in China. The two companies will cooperate on selling olmesartan medoxomil, known as Benicar in the US and Olmetec in the EU and Canada. It is a member of the angiotensin II receptor antagonist class of drugs. The potential market in China is huge. Pfizer and Daiichi Sankyo overlooked past differences to forge the agreement. More details....
